Niagen Bioscience reports Q1 EPS 7c, consensus 6c

Reports Q1 revenue $31.5M, consensus $31.03M. The company said, “We delivered $31.5 million of net sales and $6.3 million of net income for the first quarter. Our results reflect continued execution across the business, including growth in our e-commerce channel and progress across key strategic initiatives. We are advancing our scientific leadership and expanding our commercial reach while remaining focused on disciplined investment and long-term value creation from our NAD+ platform.”